Esinli EcoCapture™ Israel Health Fund
Clinical depth, global reach
Israel's health tech ecosystem combines military-grade engineering talent, serial founder density, and FDA-first market orientation to produce capital-efficient companies built for global medtech and digital health acquirers.
Fund at a glance
Fund term
10–12 years
Deployment period
3–4 years
Underlying managers
15–20
Reporting
Quarterly
Indicative and subject to final fund documentation. Minimum commitments and complete terms are provided in offering materials.
Ecosystem Intelligence
Structural characteristics and sector analysis
Profile
Digital health & medical devices (78% of health VC)
Early-stage (seed–Series B)
$1.2B deployed → $540M single exit (2025)
>90% export-oriented (US-first)
~1,350 active health startups
$17.7B total tech exits in 2025 (1.6x capital deployed)
IDF Talpiot + Technion/TAU (1,648 alumni founders)
1 in 22 startups led by a repeat founder
Sector Strength Analysis
Venture capital allocation by sub-sector (Israel Health vs. Global). Figures are directional estimates synthesized from primary data providers — see offering materials for full sourcing.
Why Israel Health
What distinguishes this opportunity
Military-to-health talent pipeline creates asymmetric founder quality
The IDF's Talpiot program produces graduates who found roughly 10% of Israeli unicorns at a rate five times that of Stanford's MBA program, generating founders with systems-engineering discipline that translates directly into medical device innovation.
Global-first market orientation forces capital efficiency
Israel's small domestic market makes export an unavoidable stage for health tech companies, with founders increasingly pursuing sophisticated FDA-first strategies around CPT codes, CMS policy, and payer evidence.
Serial founder density accelerates ecosystem learning curves
One in every 22 Israeli startups is led by a repeat founder — the highest ratio globally — meaning founders who have navigated FDA clearance and strategic acquisition bring that institutional knowledge to subsequent ventures.
Portfolio Construction
How the fund operates
Multi-manager diversification within Israel Health
The fund invests across venture capital managers operating in Israel Health, providing exposure to a diversified set of underlying companies while reducing dependency on any single manager's performance or selection capability.
Vintage-aware allocation strategy
Capital is deployed across multiple investment years to capture different market cycles and valuation environments. This vintage diversification reduces exposure to any single period's pricing dynamics.
Governance and oversight
The Investment Committee conducts systematic due diligence on manager selection, monitors portfolio composition, and maintains ongoing communication with underlying funds. Quarterly reporting provides transparency into developments.
Selection
The framework, applied to Israel Health
Every manager in this fund is evaluated through Esinli's documented selection framework: evidence-ranked criteria, a pass/fail compliance gate, and an Investment Committee decision recorded with its reasoning. The criteria are public; the weightings are proprietary and disclosed in offering materials.
Read the selection framework →Where the framework concentrates here
Track Record
Notable exits from this space
SoniVie
Itamar Medical
Innovalve Bio Medical
Zebra Medical Vision
MetaSight Diagnostics
Examples shown reflect historical outcomes within this ecosystem and sector, and are not investments made by Esinli funds. Past performance does not guarantee future results.
Ecosystem Context
Funds active in this space
Peregrine Ventures
aMoon Fund
Pontifax Venture Capital
Accelmed
OrbiMed Israel Partners
ALIVE Israel HealthTech Fund
Sanara Capital
Shoni Health Ventures
Bridges Israel
eHealth Ventures
Funds listed are provided for ecosystem context only. Esinli does not commit to investing in any specific manager. Actual allocations are determined by the Investment Committee based on fund availability, terms, and portfolio construction objectives.
Investor Considerations
Frequently asked questions
What is the minimum investment?
Minimum commitments are set per fund based on investor type and structure, and are provided in offering materials upon request. Contact us to discuss your allocation.
What is the expected holding period?
Venture capital fund-of-funds typically have 10–12 year fund lifecycles, with distributions occurring as underlying portfolio companies achieve liquidity events. This is a long-term investment structure designed to capture full innovation cycles.
Am I locked in until fund termination?
This is a long-term venture investment, and investors should plan to hold for the fund lifecycle. Liquidity before termination may be possible through third-party secondary market transactions, subject to fund terms. Availability, pricing, and timing depend on market conditions and are not guaranteed.
How does sector and geographic concentration affect risk?
This fund's focus on Israel Health creates intentional exposure rather than accidental concentration. Diversification across managers and hundreds of underlying companies within this space reduces single-manager and single-company risk. Investors seeking broader diversification can allocate across multiple EcoCapture™ funds.
What are the fees?
Fee structure follows fund-of-funds conventions: management fees cover Investment Committee oversight, due diligence, and ongoing portfolio management. Detailed fee disclosure is provided in offering materials. We maintain transparency on both direct fees and underlying fund fees.
Questions about this fund?
Schedule a conversation to discuss Israel Health, portfolio construction, and how this fund fits within a broader allocation strategy.